Sagimet Biosciences Inc. (NASDAQ: SGMT)

Sagimet Biosciences Inc. (SGMT) is a clinical-stage biopharmaceutical company operating in the biotechnology industry. The company is renowned for its development of novel therapeutics, specifically fatty acid synthase (FASN) inhibitors, which target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate.

Sagimet Biosciences Inc.'s main business activities revolve around the research, development, and clinical testing of FASN inhibitors. These activities are primarily focused on three key areas: MASH (Metabolic Dysfunction-Associated Steatohepatitis), acne, and oncology. The company's operations span across various countries, with a significant presence in the United States and China.

The company generates revenue primarily through its lead drug candidate, denifanstat. This oral, once-daily pill is being developed for the treatment of MASH, a progressive liver disease characterized by the accumulation of excess fat in the liver, inflammation, and fibrosis. Denifanstat has shown promising results in clinical trials, with Sagimet Biosciences Inc. completing two Phase 2 clinical trials, FASCINATE-1 and FASCINATE-2, which achieved statistically significant results on primary and multiple secondary endpoints. The company is currently designing a pivotal Phase 3 program for denifanstat in MASH, which it plans to initiate in the second half of 2024.

In addition to MASH, denifanstat is also being developed for the treatment of moderate to severe acne vulgaris. Ascletis Pharma, a subsidiary of Ascletis Pharma, has completed a Phase 2 clinical trial and announced positive results, with denifanstat achieving statistically significant improvements in total lesion count and inflammatory lesion count. A Phase 3 clinical trial is currently underway in China.

Furthermore, Sagimet Biosciences Inc. is exploring the potential of denifanstat in combination with other classes of oncology drugs to treat specific subsets of solid tumors that are FASN-dependent. A Phase 1 clinical trial has been completed, and a Phase 3 registrational trial is currently underway in China in patients with recurrent glioblastoma multiforme.

Sagimet Biosciences Inc. holds a strong competitive position in the industry due to its unique mechanism of action that targets the three key drivers of MASH pathogenesis: steatosis, inflammation, and fibrosis. The company's FASN inhibitors have shown promising results in clinical trials, and its precision medicine approach using non-invasive tests (NITs) to identify patients who will benefit from denifanstat is a significant differentiator.

The company's customers include Ascletis Pharma, which has licensed the development and commercialization rights to denifanstat in Greater China.

The brand names and/or trade names of Sagimet Biosciences Inc.'s products and services include denifanstat and its application in MASH, acne, and oncology. These designations reflect the company's commitment to developing innovative therapeutic solutions for a range of medical conditions.